Jacques Rossouw

Jacques Rossouw joined our group as a PhD candidate in 2025.

He holds a B.Pharm and an MSc in Pharmaceutics (cum laude) from North-West University, obtained in 2016 and 2018, respectively. His postgraduate research focused on characterising small cell lung cancer (SCLC) cells for incorporation into a 3D cell culture model for preclinical drug development.

Following his graduation, Jacques gained experience as a registered pharmacist in the pharmaceutical and medical device industries. During this time, he also completed a Postgraduate Diploma in Medicines Development (cum laude) through Stellenbosch University, part-time. Motivated by a growing interest in quantitative pharmacology, Jacques transitioned into the field of pharmacometrics.

Current Research Projects:

Jacques contributes to the following clinical pharmacology studies:

• METHOD: A Prospective, Open-Label Phase 2A Study of the Safety and Tolerability of Metformin in Combination with Standard Antimicrobial Treatment for Pulmonary Tuberculosis in People Co-infected with HIV.
• BALANCE: An open-label randomised controlled trial evaluating the benefit-risk of 1-month rifapentine and isoniazid (1HP) compared to standard of care to prevent tuberculosis and reduce morbidity in people with diabetes.

Research interests

Nonlinear mixed-effects modelling of the pharmacokinetics and pharmacodynamics (PK/PD) of anti-TB and antiretroviral drugs, particularly in comorbid diabetes populations.

Software: R, NONMEM, Phoenix WinNonlin, Phoenix NLME